Results 61 to 70 of about 4,590 (196)

Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of ONWARDS 1–5

Diabetes, Obesity and Metabolism, Volume 27, Issue 6, Page 3165-3175, June 2025.
Abstract Aims To assess the treatment effects of once‐weekly insulin icodec (icodec) versus once‐daily basal insulin comparators in individuals with type 2 diabetes (T2D) according to baseline glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) and sodium‐glucose co‐transporter‐2 inhibitor (SGLT2i) use.
Tina Vilsbøll, Ariel Fu, Monika Kellerer, Bharath Kumar, Stinne Byrholdt Søgaard, Ronald Goldenberg   +5 more
wiley   +1 more source

Insulin glargine 300 U/ml in the management of diabetes: clinical utility and patient perspectives

Patient Preference and Adherence, 2016
Bastiaan E de Galan Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands Abstract: There is ongoing interest in optimizing basal insulin treatment by developing insulins with a flat pharmacological profile, a ...
de Galan BE
doaj  

The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2016
Introduction. A combination of drugs is required for treatment of obese subjects with diabetes, due to multiple pathogenic mechanisms implicated in the development of both diabetes and obesity. Objective.
Beljić-Živković Teodora, Marjanović-Petković Milica, Vuksanović Miljanka, Soldatović Ivan, Kanlić Dobrila, Topalov Drina   +5 more
doaj   +1 more source

Use of insulin glargine in dogs with diabetes mellitus [PDF]

Veterinary Record, 2012
The objective of this study was to evaluate the safety and efficacy of insulin glargine in dogs with diabetes mellitus (DM). Twelve client‐owned dogs with DM were included. All dogs received insulin glargine every 12 hours for at least six months, re‐evaluations were performed after one, two, four, eight, 12 and 24 weeks and included clinical signs ...
Fracassi, F, Boretti, Felicitas S, Sieber-Ruckstuhl, Nadja S, Reusch, Claudia E   +3 more
openaire   +5 more sources

Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme

Diabetes, Obesity and Metabolism, Volume 27, Issue 6, Page 3223-3232, June 2025.
Abstract Aims This participant‐level exploratory analysis assessed the continuous time spent in glycaemic control and/or with sustained weight reductions with tirzepatide treatment in participants with type 2 diabetes (T2D) from the SURPASS programme.
Brandon K. Bergman, Julio Rosenstock, W. Timothy Garvey, Rachel L. Batterham, Yanyun Chen, Minzhi Liu, Palash Sharma, Chrisanthi A. Karanikas, Vivian T. Thieu   +8 more
wiley   +1 more source

Insulin glargine does not increase the risk of malignancy.Synopsis of the article ?Combined randomised controlled trial experience of malignancies in studies using insulin glargine?byHome P.D. & Lagarenne P. (Diabetologia 2009, vol. 52 (12): 2499-2506)

Сахарный диабет, 2010
Results of 31 controlled randomized studies of insulin glargine given to patients with diabetes mellitus are reviewed to evaluate the frequency of malignantneoplasms.
Marina Vladimirovna Shestakova, Irina Vladimirovna Glinkina   +1 more
doaj   +1 more source

Reinforcement Learning-Based Adaptive Insulin Advisor for Individuals with Type 1 Diabetes Patients under Multiple Daily Injections Therapy [PDF]

arXiv, 2019
The existing adaptive basal-bolus advisor (ABBA) was further developed to benefit patients under insulin therapy with multiple daily injections (MDI). Three different in silico experiments were conducted with the DMMS.R simulator to validate the approach of combined use of self-monitoring of blood glucose (SMBG) and insulin injection devices, e.g ...
arxiv  

Insulin Glargine Safety in Pregnancy [PDF]

Diabetes Care, 2009
OBJECTIVEInsulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased incidence of hypoglycemia provide potential advantages for its use in pregnancy.
Paul M. Yip, Gideon Koren, Denice S. Feig, Erika K. Pollex, Angelika Lubetsky   +4 more
openaire   +3 more sources

Safety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico

Diabetes, Obesity and Metabolism, Volume 27, Issue 6, Page 3389-3396, June 2025.
Abstract Aims To evaluate the safety and effectiveness of iGlarLixi in people with type 2 diabetes mellitus (T2DM) in clinical practice in Mexico. Materials and Methods This was a prospective, observational, multicentre study in adults with T2DM who were prescribed iGlarLixi in routine clinical practice in Mexico. The participants were followed for 24 ±
Juan Rosas‐Guzman, Alberto Navarro‐Lara, Maria Elena Sañudo‐Maury, Luis Anguiano, Leobardo Sauque‐Reyna   +4 more
wiley   +1 more source

Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta‐analysis of non‐Asian studies

Diabetes, Obesity and Metabolism, Volume 27, Issue 6, Page 3410-3418, June 2025.
Abstract Aims To estimate the relative treatment effect of iGlarLixi (a fixed‐ratio combination of insulin glargine 100 U/mL plus lixisenatide) versus premixed insulin IDegAsp (insulin degludec plus insulin aspart) in people with type 2 diabetes (T2D) who advanced from basal insulin to iGlarLixi or IDegAsp in non‐Asian studies.
Philip Home, Felipe Lauand, Khier Djaballah, Xuan‐Tony Li, Khadija Hafidh, Roopa Mehta, Khadra Faraoun, İnan Anaforoğlu, Paul Serafini, Mir‐Masoud Pourrahmat   +9 more
wiley   +1 more source